The FDA wants to study DTC tactics
The agency has proposed two studies to investigate the use of superimposed text and the use of animated characters.
DTC
Omnicom formalizes health group led by CDM’s Wise
The division, dubbed Omnicom Health Group, claims to serve 70% of the top 100 pharma brands.
Five things for pharma marketers to know: Thursday, February 18, 2016
Lawmaker seeks to stop DTC ads for newly approved drugs; testosterone therapy helps sexual function; the FDA requests more data about Catalyst’s rare drug
The best and worst pharma celebrity moments
We present to you our picks for the best and worst moments in celebrity healthcare spokespersonship—plus a few more that, frankly, we can’t find anywhere.
Celebrity pharma ads: Opportunity or PR disaster?
Tapping celebrities for brand or awareness campaigns ensures a high degree of attention, but such arrangements come with concerns that “regular” ones do not.
Is This the End of Agency Diversification?
DTC and OTC/wellness can borrow from mainstream consumer shops. Professional marketing may pose a tougher sell.
BMS CEO defends use of DTC to promote cancer drug
The drugmaker’s CEO said the campaign helps dispel pessimism created from a history of cancer drugs that lack “significant value.”
What the AMA’s Proposed DTC Ban Overlooks
While DTC advertising does significantly impact consumer demand, most evidence suggests the majority of this demand benefits the overall state of consumer health.
Characters in DTC Ads Used with Little Reason
Many of the characters we are now meeting do not appear to be directed at a patient insight or purposefully used to de-stigmatize a disease.
Five things for pharma marketers to know: Wednesday, January 6, 2016
Lilly’s Jardiance starting to gain market share; Merck “raring” to make acquisitions; Sanofi said it will stop marketing Afrezza
